Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review
Open Access
- 7 April 2020
- journal article
- Published by Royal College of General Practitioners in BJGP Open
Abstract
Background On the 11 March 2020, the World Health Organization (WHO) declared that COVID-19 was a pandemic. To date, there are no medical treatments for COVID-19 with proven effectiveness. Novel treatments and/or vaccines will take time to be developed and distributed to patients. In light of this, there has been growing interest in the use of existing medications, such as chloroquine (CQ) and hydroxychloroquine (HCQ), as potential treatments of this disease. Aim To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19. Design & setting A rapid review of the literature was conducted. Method Electronic searches in PubMed and Google Scholar were conducted on 21 March 2020. A further search was conducted in Google for relevant literature on 28 March 2020. Results There is limited evidence of in vitro activity of CQ/HCQ against SARS-CoV-2. A number of in vivo clinical trials are underway. The empirical data available from two of these trials reveal conflicting results. Both trials are characterised by small numbers of participants (n = 30 and n = 36) and suffer methodological limitations. No medium or long-term follow-up data is available. Conclusion At present, there is insufficient evidence to determine whether CQ/HCQ are safe and effective treatments for COVID-19. High quality, adequately powered randomised clinical trials in primary and secondary care settings are urgently required to guide policymakers and clinicians. These studies should report medium- and long-term follow-up results, and safety data.Keywords
This publication has 30 references indexed in Scilit:
- The enigma of the clandestine association between chloroquine and HIV‐1 infectionHIV Medicine, 2015
- Quinoline-based antimalarial drugs: a novel class of autophagy inhibitorsNeurosurgical Focus, 2015
- Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn MiceAntimicrobial Agents and Chemotherapy, 2009
- Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseasesRheumatology, 2007
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirology Journal, 2005
- Effects of chloroquine on viral infections: an old drug against today's diseasesThe Lancet Infectious Diseases, 2003
- Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicityAmerican Journal of Ophthalmology, 2002
- Retinal toxicity in long term hydroxychloroquine treatment.Annals Of The Rheumatic Diseases, 1996
- The ocular safety of hydroxychloroquineSeminars in Arthritis and Rheumatism, 1993
- Restrictive cardiomyopathy caused by chloroquine.Heart, 1993